|
1
|
Friedenreich CM: Physical activity and
breast cancer: Review of the epidemiologic evidence and biologic
mechanisms. Recent Results Cancer Res. 188:125–139. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng L, Zhou B, Meng X, Zhu W, Zuo A,
Wang X, Jiang R and Yu S: A model of spontaneous mouse mammary
tumor for human estrogen receptor- and progesterone
receptor-negative breast cancer. Int J Oncol. 45:2241–2249.
2014.PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guan Y, Song H, Zhang G and Ai X:
Overexpression of flotillin-1 is involved in proliferation and
recurrence of bladder transitional cell carcinoma. Oncol Rep.
32:748–754. 2014.PubMed/NCBI
|
|
5
|
Babuke T and Tikkanen R: Dissecting the
molecular function of reggie/flotillin proteins. Eur J Cell Biol.
86:525–532. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y,
Wang X, Li J and Song L: Knockdown of FLOT1 impairs cell
proliferation and tumorigenicity in breast cancer through
upregulation of FOXO3a. Clin Cancer Res. 17:3089–3099. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Langhorst MF, Reuter A and Stuermer CA:
Scaffolding microdomains and beyond: The function of
reggie/flotillin proteins. Cell Mol Life Sci. 62:2228–2240. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hazarika P, McCarty MF, Prieto VG, George
S, Babu D, Koul D, Bar-Eli M and Duvic M: Up-regulation of
Flotillin-2 is associated with melanoma progression and modulates
expression of the thrombin receptor protease activated receptor 1.
Cancer Res. 64:7361–7369. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu Z, Wang J, Sun Z, Sun X, Wang Z and Xu
H: Flotillin2 expression correlates with HER2 levels and poor
prognosis in gastric cancer. PLoS One. 8:e623652013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rickman DS, Millon R, De Reynies A, Thomas
E, Wasylyk C, Muller D, Abecassis J and Wasylyk B: Prediction of
future metastasis and molecular characterization of head and neck
squamous-cell carcinoma based on transcriptome and genome analysis
by microarrays. Oncogene. 27:6607–6622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan Y, Yang FQ, Zhang HM, Che J and Zheng
JH: Up-regulation of flotillin-2 is associated with renal cell
carcinoma progression. Tumour Biol. 35:10479–10486. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wen Q, Li J, Wang W, et al: Increased
expression of flotillin-2 protein as a novel biomarker for lymph
node metastasis in nasopharyngeal carcinoma. PLoS One.
9:e1016762014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Yang Q, Guo L, Li XH, Zhao XH,
Song LB and Lin HX: Flotillin-2 is associated with breast cancer
progression and poor survival outcomes. J Transl Med. 11:1902013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pust S, Dyve AB, Torgersen ML, van Deurs B
and Sandvig K: Interplay between toxin transport and flotillin
localization. PLoS One. 5:e88442010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hahn WC, Dessain SK, Brooks MW, King JE,
Elenbaas B, Sabatini DM, DeCaprio JA and Weinberg RA: Enumeration
of the simian virus 40 early region elements necessary for human
cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie G, Tang H, Wu S, Chen J, Liu J and
Liao C: The cyclin-dependent kinase inhibitor SNS-032 induces
apoptosis in breast cancer cells via depletion of Mcl-1 and
X-linked inhibitor of apoptosis protein and displays antitumor
activity in vivo. Int J Oncol. 45:804–812. 2014.PubMed/NCBI
|
|
17
|
Xie G, Zhu X, Li Q, et al: SZ-685C, a
marine anthraquinone, is a potent inducer of apoptosis with
anticancer activity by suppression of the Akt/FOXO pathway. Br J
Pharmacol. 159:689–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakamura N, Ramaswamy S, Vazquez F,
Signoretti S, Loda M and Sellers WR: Forkhead transcription factors
are critical effectors of cell death and cell cycle arrest
downstream of PTEN. Mol Cell Biol. 20:8969–8982. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cardozo T and Pagano M: The SCF ubiquitin
ligase: Insights into a molecular machine. Nat Rev Mol Cell Biol.
5:739–751. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burgering BM: A brief introduction to
FOXOlogy. Oncogene. 27:2258–2262. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu W, Wang J, Ma L, Tang X, Qiao Y, Pan Q,
Yu Y and Sun F: CD166 plays a pro-carcinogenic role in liver cancer
cells via inhibition of FOXO proteins through AKT. Oncol Rep.
32:677–683. 2014.PubMed/NCBI
|
|
23
|
Doerfler W, Hohlweg U, Müller K, Remus R,
Heller H and Hertz J: Foreign DNA integration - perturbations of
the genome - oncogenesis. Ann NY Acad Sci. 945:276–288. 2001.
View Article : Google Scholar
|
|
24
|
Arden KC: FoxOs in tumor suppression and
stem cell maintenance. Cell. 128:235–237. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park SH, Lee JH, Berek JS and Hu MC:
Auranofin displays anticancer activity against ovarian cancer cells
through FOXO3 activation independent of p53. Int J Oncol.
45:1691–1698. 2014.PubMed/NCBI
|
|
26
|
Huang H, Regan KM, Wang F, Wang D, Smith
DI, van Deursen JM and Tindall DJ: Skp2 inhibits FOXO1 in tumor
suppression through ubiquitin-mediated degradation. Proc Natl Acad
Sci USA. 102:1649–1654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seoane J, Le HV, Shen L, Anderson SA and
Massagué J: Integration of Smad and forkhead pathways in the
control of neuroepithelial and glioblastoma cell proliferation.
Cell. 117:211–223. 2004. View Article : Google Scholar : PubMed/NCBI
|
